Clinical Trials
14 trialsNCT04975555 2026-06-03
Study to Evaluate the Role of Siltuximab in Treatment of Cytokine Release Syndrome (CRS) and Immune Effector Cell Associated Neurotoxicity (ICANS) Related to CAR-T Cell Therapy
University of Alabama at Birmingham
Phase 2 Completed
NCT07499128 2026-06-01
Continuous Temperature Monitoring (CTM) for Cytokine Release Syndrome (CRS), an Immune-Related Adverse Event
National Institutes of Health Clinical Center (CC)
Phase NA Enrolling by invitation
NCT06806033 2026-05-26
A Study to Evaluate the Optimization of the Cytokine Release Syndrome Profile for Glofitamab in Combination With Gemcitabine Plus Oxaliplatin in Participants With Relapsed/Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma
Hoffmann-La Roche
Phase 2 Recruiting
NCT07502118 2026-03-30
NexCAR19
Health Institutes of Turkey
Phase 2/3 Recruiting
NCT07390071 2026-02-05
Multimodal Telerehabilitation in Patients Undergoing CAR-T Cell Immunotherapy
University of Utah
Phase NA Recruiting
NCT07166549 2025-12-24
BaseCAR-01
University Hospital, Basel, Switzerland
Phase 1 Not yet recruiting
NCT03696784 2025-12-08
Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma
UNC Lineberger Comprehensive Cancer Center
Phase 1 Active not recruiting
NCT04150913 2025-11-25
A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity
Massachusetts General Hospital
Phase 2 Completed
NCT03016377 2025-10-27
Administration of Autologous CAR-T CD19 Antigen With Inducible Safety Switch in Patients With Relapsed/Refractory ALL
UNC Lineberger Comprehensive Cancer Center
Phase 1/2 Active not recruiting
NCT06703216 2025-06-15
PACER
Ann & Robert H Lurie Children's Hospital of Chicago
Phase 1/2 Not yet recruiting
NCT06447376 2025-05-11
Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Prior to Epcoritamab
Case Comprehensive Cancer Center
Phase 1 Recruiting
NCT04466098 2025-01-29
Multiple Dosing of Mesenchymal Stromal Cells in Patients With ARDS (COVID-19)
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT05510596 2024-08-09
MR-ICANS
University Hospital, Montpellier
Phase NA Completed
NCT04358406 2023-11-28
Rhu-pGSN for Severe Covid-19 Pneumonia
BioAegis Therapeutics Inc.
Phase 2 Completed